NCT06162455 is a NA clinical trial of Sham treatment in Nosocomial Pneumonia, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT06162455?

NCT06162455 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT06162455?

Interventions in NCT06162455: Sham treatment, 200- ppm NO.

What condition does NCT06162455 study?

NCT06162455 studies Nosocomial Pneumonia.

Is NCT06162455 still recruiting?

NCT06162455 is currently completed. Last updated 8 March 2024.

Last reviewed 2024-03-08 · How we verify

NCT06162455

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-dose Inhaled NO Therapy for the Prevention of Nosocomial Pneumonia After Cardiac Surgery With CPB

Completed NA Last updated 8 March 2024

What this trial tests

NA trial testing Sham treatment in Nosocomial Pneumonia in 74 participants. Completed in 6 February 2024.

Timeline

17 November 2023

Primary endpoint
15 January 2024

6 February 2024

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	74
Start date	17 November 2023
Primary completion	15 January 2024
Estimated completion	6 February 2024
Sites	1 location across Russia

Drugs / interventions tested

Sham treatment — full drug profile →
200- ppm NO — full drug profile →

Conditions studied

Nosocomial Pneumonia — all drugs for Nosocomial Pneumonia →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

18 and older, any sex, with Nosocomial Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this single-center, prospective, randomized, controlled, pilot study is to test the hypothesis that inhalation of NO 200 ppm prevents the development of nosocomial pneumonia in patients at risk after cardiac surgery with CPB. The study is interventional. Examination and treatment of patients is carried out in accordance with the approved standards of medical care for the relevant diseases. During the study, no experimental or unregistered (not approved for use) medical or diagnostic procedures in the territory of the Russian Federation will be carried out. The study includes patients admitted to the Cardiac Surgery Department of Cardiology Research Institute of Tomsk National Research Medical Center for elective surgery with CPB.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antimicrobial Resistance: The Answers.
Millar BC, Cates MJ, Torrisi MS, Round AJ, et al · · 2026 · PMID 41727556 · DOI 10.3389/bjbs.2026.15559

Verify or expand the search:

Other trials of Sham treatment

Trials testing the same drug.

NCT07480083 — Low-level Laser Therapy in Pain and Perineal Healing in the Immediate Postpartum Period: a Randomized Clinical Trial. · NA · not yet recruiting
NCT07367438 — Effect of Subthreshold Stimulation on Fatigue in Rheumatoid Arthritis · NA · not yet recruiting
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed
NCT06738667 — Acupuncture for Painful Temporomandibular Disorder · NA · not yet recruiting
NCT06826144 — Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracran · NA · not yet recruiting

Other recruiting trials for Nosocomial Pneumonia

Currently open trials in the same condition.

NCT06691399 — Role of Oral Care in Prevention of Nosocomial Pneumonia Among COPD Patients · NA · recruiting
NCT06170372 — High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia · NA · recruiting

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06162455 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 8 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06162455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing